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Sir, 
We read with interest the review by Dr Fornaro and coworkers referring to the loss of efficacy of 
antidepressant drugs in patients with major depressive disorder (MDD) [1]. We agree that this is an issue of 
extreme importance from a pharmacological and clinical point of view.  
In line with these considerations and in order to characterise further this phenomenon in clinical practice, we 
believe it may be of interest to report here on our investigation about drug tolerance in patients treated with 
selective serotonin and serotonin-norepinephrine uptake inhibitors (SSRIs and SNRIs), first-choice agents 
for the treatment of MDD [2]. This analysis was done on post-marketing data deriving from spontaneous 
reporting of suspected adverse drug reactions (ADRs) to the FDA Adverse Event Reporting System 
(FAERS), which represent a useful source of real-world data.  
We identified 8.616.488 reports in the period 2004-2015 presenting either an SSRI or an SNRI as the only 
suspected drug and “major depressive disorder” as indication of the treatment.  
We selected 2.923 reports including tachyphylaxis, drug tolerance, increased drug tolerance and drug 
inefficacy. In order to distinguish tolerance occurrence from cases where the drug was shown to be 
ineffective from the beginning of treatment, in accordance with clinical guidelines [3,4], we set 24 weeks as 
the cut-off time to differentiate between “drug inefficacy”, i.e. lack of pharmacological response within 180 
days, and “tolerance”, defined as an initial response to therapy with subsequent loss of therapeutic response.  
806 reports included both the start date of drug administration and the reaction date, which allowed us to 
accurately evaluate drug inefficacy/tollerance over the period of administration. We identified 490 cases of 
drug inefficacy (60.79%) and 316 cases of drug tolerance (39.21%). There was no significant difference 
between male and female patients in terms of drug tolerance rate (34.63% vs 40.88%) and mean treatment 
duration before tolerance appearance (1143.86 ± 1459.61 vs 1138.23 ± 1319.94 days). We also observed that 
the SNRIs vs SSRIs showed a significantly higher percentage of drug tolerance (46.37% vs 33.48% 
p=0.0002). The drug classes also showed a significant difference in terms of time required to develop drug 
tolerance (1410.45 ± 1546.71 days for SSRIs and 879.28 ± 1080.12 days for SNRIs p=0.0005). Ultimately, 
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our analysis suggests that, in patients responding to treatment, SSRIs might be more suitable than SNRIs for 
the long treatment of MDD.  
The appraisal of the tolerance phenomenon may yield important insights in relation to the long-term 
treatment of MDD and achievement of enduring effects of antidepressant drugs. Likewise, prospective 
randomised controlled trials should be encouraged, as they would yield data as to whether the risk for 
antidepressant tachyphylaxis is an event common to most treated patients or whether – as Dr Fornaro pointed 
out - there are specific risk factors and/or clinical and therapeutic issues (also including presence of residual 
symptoms, serotonergic antidepressant-induced apathy, drug dosage, efficacy/tolerability balance) that might 
predispose some depressed patients to this condition. 
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